The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary ...

Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...

Critical Path Institute® (C-Path) and Boston Medical Center (BMC) published results for six biomarkers that could improve the early and accurate detection of kidney injury, leading to both the ...